keyword
MENU ▼
Read by QxMD icon Read
search

infliximab serum

keyword
https://www.readbyqxmd.com/read/28817809/evaluation-of-infliximab-therapy-in-children-with-crohn-s-disease-using-trough-levels-predictors
#1
Jan Ohem, Ondrej Hradsky, Kristyna Zarubova, Ivana Copova, Petra Bukovska, Richard Prusa, Karin Malickova, Jiri Bronsky
BACKGROUND: In adults, infliximab (IFX) levels correlate with disease activity, and antibodies to IFX (ATIs) predict treatment failure. We aimed to determine the association of IFX levels and ATIs with disease activity in a paediatric population. We prospectively collected blood, stool, and clinical data from 65 patients (age 10.5-15.1 years) with Crohn's disease (CD) before IFX administration, and measured IFX trough levels, ATIs, and faecal calprotectin levels (CPT). Samples were collected during maintenance therapy...
August 18, 2017: Digestive Diseases
https://www.readbyqxmd.com/read/28805137/differential-influences-of-fc-gamma-receptor-blocking-on-the-effects-of-certolizumab-pegol-and-infliximab-on-human-monocytes
#2
Takayuki Hoshiyama, Yu Matsueda, Toshihiro Tono, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata
OBJECTIVES: To compare the effects of certolizumab pegol (CZP) and infliximab (IFX) on human monocytes. METHODS: Highly purified monocytes from healthy donors were cultured with CZP, IFX, control IgG1, or polyethylene glycol (PEG) at pharmacological attainable concentrations in culture medium with 10% autologous normal human serum (NHS) or with fetal bovine serum (FBS) for 24 h, after which the supernatants were replaced by fresh culture medium containing LPS...
August 14, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28761564/predictive-value-of-serum-infliximab-levels-at-induction-phase-in-rheumatoid-arthritis-patients
#3
Jurado Teresa, Plasencia-Rodríguez Chamaida, Martínez-Feito Ana, Navarro-Compán Victoria, Rispens Theo, Vries Annick, Bloem Karien, Olariaga Eva-María, Diego Cristina, Villalba Alejandro, Peiteado Diana, Nuño Laura, Bonilla Maria-Gema, Balsa Alejandro, Pascual-Salcedo Dora
BACKGROUND: The Infliximab, has proven effective in treating rheumatoid arthritis (RA). A good clinical response is usually associated with high serum drug levels. Development of antibodies toward Infliximab (ATI) can increase drug clearance, leading to treatment failure. AIMS: To analyze whether serum Infliximab trough levels (ITL) at the induction phase are associated with Infliximab clearance and clinical outcomes at week(W) 54 and to investigate the association with immunogenicity development...
2017: Open Rheumatology Journal
https://www.readbyqxmd.com/read/28749002/-natalizumab-for-the-treatment-of-crohn%C3%A2-s-disease-report-of-three-cases
#4
Daniela Fluxá, Patricio Ibáñez, Lilian Flores, Carolina Figueroa, Jaime Lubascher, Udo Kronberg, Daniela Simian, Gonzalo Pizarro, Paola Toche, Rodrigo Quera
Anti-tumor necrosis factor-α (TNF) agents have dramatically changed the management of Crohn’s Disease (CD). However, a significant number of these patients do not respond at all or cease to respond to antibodies against TNF. In this clinical situation, the options include intensification of anti-TNF therapy by either increasing the dose or by shortening the administration interval, the use of a second anti-TNF or medications with a different mechanism of action. Among the later, Natalizumab, a humanized IgG4 monoclonal antibody against α4β1 and α4β7 integrins, is safe and effective in inducing and maintaining remission in active CD patient’s refractory to anti-TNF...
April 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28743358/higher-body-mass-index-and-anti-drug-antibodies-predict-the-discontinuation-of-anti-tnf-agents-in-korean-patients-with-axial-spondyloarthritis
#5
Jiwon Hwang, Hye-Mi Kim, Hyemin Jeong, Jaejoon Lee, Joong Kyong Ahn, Eun-Mi Koh, Eun-Suk Kang, Hoon-Suk Cha
OBJECTIVE: The development of anti-drug antibodies against tumor necrosis factor inhibitors is a likely explanation for the failure of TNF-inhibitors in patients with spondyloarthritis. Our study determined the existence and clinical implications of ADAbs in axial spondyloarthritis patients. METHODS: According to the Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis, patients treated with adalimumab or infliximab were recruited consecutively...
July 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28743169/development-and-validation-of-an-optical-biosensor-for-rapid-monitoring-of-adalimumab-in-serum-of-patients-with-crohn-s-disease
#6
Sumin Bian, Jiadi Lu, Filip Delport, Séverine Vermeire, Dragana Spasic, Jeroen Lammertyn, Ann Gils
Therapeutic drug monitoring of adalimumab is recommended to improve therapeutic outcome in patients with Crohn's disease. Performing an ELISA requires a rather long time-to-result and the necessity of collecting multiple samples in order to decrease the cost per adalimumab determination. In this study, we aim to develop and validate a rapid assay suitable for measuring a single adalimumab serum sample using a fiber-optic surface plasmon resonance (FO-SPR) based sensor. Therefore, we have immobilized MA-ADM28B8 as capture antibody on a FO-probe and conjugated MA-ADM40D8 as detecting antibody to gold nanoparticles...
July 25, 2017: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28737646/crp-albumin-ratio-an-early-predictor-of-steroid-responsiveness-in-acute-severe-ulcerative-colitis
#7
David J Gibson, Karen Hartery, Jayne Doherty, Jack Nolan, Denise Keegan, Kathryn Byrne, Sean T Martin, Maire Buckley, Juliette Sheridan, Gareth Horgan, Hugh E Mulcahy, Garret Cullen, Glen A Doherty
INTRODUCTION: Identifying hospitalized patients with acute severe ulcerative colitis (ASUC) who will be refractory to corticosteroid therapy and require rescue therapy remains difficult. Hypoalbuminemia worsens with time during hospitalization and is associated with rapid clearance of and reduced response to infliximab (IFX) rescue. Early use of rescue therapy may therefore be more effective. Simple clinical and laboratory predictors of corticosteroid responsiveness would facilitate earlier use of rescue therapy...
July 21, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28721978/noninvasive-biomarkers-as-surrogate-predictors-of-clinical-and-endoscopic-remission-after-infliximab-induction-in-patients-with-refractory-ulcerative-colitis
#8
Elham A Hassan, Haidi K Ramadan, Ali A Ismael, Khaled F Mohamed, Madiha M El-Attar, Ihab Alhelali
BACKGROUND/AIMS: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after biological therapy, monitoring clinical and endoscopic responses is fundamental. We aimed to investigate and compare the predictive power of different noninvasive parameters for clinical remission and mucosal healing after infliximab induction therapy in refractory UC patients. PATIENTS AND METHODS: Serum and fecal biomarkers, including hemoglobin, white blood cells, erythrocyte sedimentation rate, C-reactive protein (CRP), and fecal calprotectin (FC), and colonoscopy were assessed in 44 patients with refractory UC before and after (week 12) infliximab induction...
July 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28716826/il-10-producing-infliximab-specific-t-cells-regulate-the-antidrug-t-cell-response-in-exposed-patients
#9
Alessandra Vultaggio, Francesca Nencini, Sara Pratesi, Daniele Cammelli, Maria Totaro, Sergio Romagnani, Enrico Maggi, Andrea Matucci
Infliximab (IFX) is a chimeric mAb that can lead to the appearance of anti-drug Abs. Recent research has identified the presence of circulating IFX-specific T cells in treated patients. The aim of the study was to analyze the functional characteristics of IFX-specific T cells, in particular their capability to produce biologically active regulatory cytokines. Drug-stimulated PBMCs or coculture systems were used to detect memory T cells in treated patients. The cytokines produced by IFX-specific T cells, T cell lines, and T cell clones were evaluated at the mRNA and protein levels...
July 17, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28644181/serum-interleukin-9-levels-predict-disease-severity-and-the-clinical-efficacy-of-infliximab-in-patients-with-crohn-s-disease
#10
Ting Feng, Baili Chen, Li Li, Shanshan Huang, Shomron Ben-Horin, Yun Qiu, Rui Feng, Manying Li, Ren Mao, Yao He, Zhirong Zeng, Shenghong Zhang, Minhu Chen
BACKGROUND: Interleukin (IL)-9 drives gut inflammation, but its role in Crohn's disease (CD) is unclear. We aimed to analyze correlations between serum IL-9 levels and disease severity and to evaluate their predictive value in relation to the clinical efficacy of infliximab (IFX) in patients with CD. METHODS: Between January 2013 and December 2015, 100 consecutive patients with active CD and 50 age- and sex-matched control individuals were recruited from a tertiary center...
June 20, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28622097/evolution-of-cytokines-and-inflammatory-biomarkers-during-infliximab-induction-therapy-and-the-impact-of-inflammatory-burden-on-primary-response-in-patients-with-crohn-s-disease
#11
Thomas Billiet, Isabelle Cleynen, Vera Ballet, Karolien Claes, Fred Princen, Sharat Singh, Marc Ferrante, Gert Van Assche, Ann Gils, Severine Vermeire
OBJECTIVE: Primary non-response to infliximab in Crohn's disease is still incompletely understood. Our aim was to further characterize the role of inflammatory burden during infliximab induction therapy. MATERIALS AND METHODS: We studied a well-characterized cohort of 201 anti-TNF naive Crohn's disease patients treated with infliximab 5mg/kg at week 0, 2, 6 and 14 who had serum samples drawn just before every infusion. All serum samples were analyzed for CRP, albumin, TNF, IFN-γ, IL-6, IL-8, IL-10, infliximab trough concentrations (in-house-developed ELISA) and antibodies to infliximab (HMSA, Prometheus Laboratories Inc...
June 16, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28618062/examining-maintenance-care-following-infliximab-salvage-therapy-for-acute-severe-ulcerative-colitis
#12
Dean Seah, Matthew C Choy, Alexandra Gorelik, William R Connell, Miles P Sparrow, Daniel van Langenberg, Geoffrey Hebbard, Gregory Moore, Peter De Cruz
BACKGROUND AND AIMS: Data supporting the optimal maintenance drug therapy & strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We aimed to evaluate maintenance & monitoring strategies employed in patients post IFX induction therapy. METHODS: Patients in 6 Australian tertiary centres treated with IFX for steroid-refractory ASUC between April 2014 & May 2015 were identified via hospital IBD & pharmacy databases...
June 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28565826/transcriptional-profiling-of-leukocytes-from-rheumatoid-arthritis-patients-before-and-after-anti-tumor-necrosis-factor-therapy-a-comparison-of-anti-nuclear-antibody-positive-and-negative-subsets
#13
Laurie S Davis, Andreas M Reimold
Anti-nuclear antibodies (ANAs) may be induced in patients with rheumatoid arthritis (RA) receiving anti-tumor necrosis factor (TNF) therapy with TNF inhibitors (TNFi), etanercept, infliximab or adalimumab. In the present study, 11 patients who were TNFi drug naive were started on TNFi at a time of high disease activity. Of these, all cases were positive for rheumatoid factor and 9 cases tested were positive for anti-citrullinated peptide (anti-CCP) antibodies prior to TNFi treatment. Peripheral blood mononuclear cells (PBMCs) and serum were collected from all patients before and after TNFi therapy...
May 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28514405/-stable-high-interleukin-17a-concentration-in-patients-with-ankylosing-spondylitis-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-during-a-year
#14
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan
AIM: To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. SUBJECTS AND METHODS: Examinations were made in 30 patients (22 (73.3%) men) aged 38.35±9.19 years with AS (modified New-York criteria, BASDAI ≥4.0; AS duration, 11.4±9.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1±7.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg/kg body weight during a year according to the recommended regimen...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28507492/long-term-treatment-of-chronic-plaque-psoriasis-with-biological-drugs-can-control-platelet-activation-targeting-the-bridge-between-inflammation-and-atherothrombosis
#15
Bartłomiej Kwiek, Joanna Narbutt, Anna Sysa-Jędrzejowska, Andrzej Langner, Aleksandra Lesiak
INTRODUCTION: Platelet activation is elevated in moderate to severe psoriasis, and the reduction in platelet activation during short-term treatment has already been demonstrated. Soluble P-selectin is a well-established marker of platelet activation. AIM: To show whether the long-term treatment of psoriasis with biological drugs can reduce elevated platelet activation. MATERIAL AND METHODS: An observational study of 27 patients with chronic plaque psoriasis, treated with infliximab, adalimumab, etanercept, or ustekinumab for up to 12 months was conducted...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28481014/infliximab-and-adalimumab-drug-levels-in-crohn-s-disease-contrasting-associations-with-disease-activity-and-influencing-factors
#16
M G Ward, B Warner, N Unsworth, S-W Chuah, C Brownclarke, S Shieh, M Parkes, J D Sanderson, Z Arkir, J Reynolds, P R Gibson, P M Irving
BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn's disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn's disease according to different disease endpoints, and factors that influence drug levels. METHODS: We performed a cross-sectional service evaluation of patients receiving maintenance infliximab or adalimumab for Crohn's disease...
July 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28465139/diagnostic-potential-of-netosis-derived-products-for-disease-activity-atherosclerosis-and-therapeutic-effectiveness-in-rheumatoid-arthritis-patients
#17
C Pérez-Sánchez, P Ruiz-Limón, M A Aguirre, Y Jiménez-Gómez, I Arias-de la Rosa, M C Ábalos-Aguilera, A Rodriguez-Ariza, M C Castro-Villegas, R Ortega-Castro, P Segui, C Martinez, R Gonzalez-Conejero, S Rodríguez-López, J A Gonzalez-Reyes, J M Villalba, E Collantes-Estévez, A Escudero, N Barbarroja, Ch López-Pedrera
OBJECTIVES: 1) To assess the association of NETosis and NETosis-derived products with the activity of the disease and the development of cardiovascular disease in RA; 2) To evaluate the involvement of NETosis on the effects of biologic therapies such as anti-TNF alpha (Infliximab) and anti-IL6R drugs (Tocilizumab). METHODS: One hundred and six RA patients and 40 healthy donors were evaluated for the occurrence of NETosis. Carotid-intimae media thickness was analyzed as early atherosclerosis marker...
April 29, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28459157/infliximab-alleviates-the-mortality-mesenteric-hypoperfusion-aortic-dysfunction-and-multiple-organ-damage-in-septic-rats
#18
Erdem Kamil Ozer, Mustafa Tugrul Goktas, Ibrahim Kilinc, Aysun Toker, Hulagu Bariskaner, Ceyhan Ugurluoglu, Alper Bektas Iskit
Tumor necrosis factor-alpha (TNF-α) is a pivotal mediator that triggers inflammatory process, oxidative stress, and multiple organ injury in sepsis. We investigated the effects of infliximab on survival, mesenteric artery blood flow (MBF), vascular reactivity, and oxidative and inflammatory injuries in cecal ligation and puncture (CLP)-induced sepsis. Wistar rats were divided into Sham, CLP, Sham+infliximab, and CLP+infliximab subgroups. Twenty-four hours before the operations, rats were injected intraperitoneally with infliximab (7 mg/kg) or vehicle (saline; 1 mL/kg)...
July 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28453755/association-of-induction-infliximab-levels-with-clinical-response-in-perianal-crohn-s-disease
#19
Yana Davidov, Bella Ungar, Haggai Bar-Yoseph, Dan Carter, Ola Haj-Natour, Miri Yavzori, Yehuda Chowers, Rami Eliakim, Shomron Ben-Horin, Uri Kopylov
Background: The association of infliximab [IFX] trough levels with clinical and endoscopic outcomes in inflammatory bowel disease is well established. However, there is scarce data regarding the association of perianal fistula response with IFX. The aim of this study was to establish whether early induction infliximab levels and anti-infliximab antibodies [ATIs] are associated with perianal fistula response. Methods: Consecutive CD patients with perianal fistulae that were treated with IFX between 2008 and 2016 were included in the study...
May 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28450388/clinical-relevance-of-detecting-anti-infliximab-antibodies-with-a-drug-tolerant-assay-post-hoc-analysis-of-the-taxit-trial
#20
Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
OBJECTIVE: To evaluate the clinical relevance of antidrug antibodies (ADAs) measured using a drug-tolerant assay in a post hoc analysis of the Trough Concentration (TC) Adapted Infliximab Treatment (TAXIT) randomised controlled trial. DESIGN: ADA in serum samples (n=221) of 76 patients enrolled in TAXIT, who presented with an infliximab TC <3 µg/mL at screening, were reanalysed after optimisation and at the end of the study using a drug-tolerant ADA assay...
April 27, 2017: Gut
keyword
keyword
43807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"